Bevacizumab Global Buyers List: A Comprehensive Guide to Importers, Procurement Trends, and Market Dynamics
Bevacizumab, a humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), has become a cornerstone in oncology treatment worldwide. As patents expire and biosimilar competition intensifies, the global buyer landscape for this critical therapeutic has evolved dramatically. This guide examines the key importers, procurement patterns, and market forces shaping Bevacizumab sourcing across international markets.
Understanding Bevacizumab: Clinical Significance and Market Position
Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that functions as an anti-angiogenic agent by inhibiting vascular endothelial growth factor. It is indicated for treating several cancers, including metastatic colorectal cancer, non-small cell lung cancer, glioblastoma, metastatic renal cell carcinoma, and cervical cancer.
The World Health Organization includes Bevacizumab on its Model List of Essential Medicines, underscoring its global importance. The WHO Expert Committee has recommended that quality-assured biosimilars be interchangeable with biological medicines on the EML and eligible for procurement at country level.
The global Bevacizumab market is projected to grow from approximately USD 7.66 billion to USD 18.46 billion by 2034, representing a compound annual growth rate of 10.26%. This expansion is driven by increasing cancer prevalence and rising demand for targeted therapies.
Top Global Bevacizumab Buyers and Importers
Leading Importers from India
India has emerged as a significant export hub for Bevacizumab, serving 346 active buyers across 100 countries with a total export value of approximately $46.9 million across 1,408 shipments. The top five buyers collectively control 71.1% of total import value, reflecting a concentrated buyer landscape.
Table 1: Top 5 Bevacizumab Importers from India
| Rank | Buyer | Country | Import Value | Market Share |
|---|---|---|---|---|
| 1 | JSC R-PHARM | Russia | $18.7M | 39.8% |
| 2 | JSC R PHARM | Russia | $4.9M | 10.5% |
| 3 | Biocon Biologics UK Limited | Netherlands | $4.9M | 10.5% |
| 4 | Bio Logic UK Ltd | Australia | $3.0M | 6.3% |
| 5 | Dr. Reddy’s Laboratories SAS | Colombia | $1.9M | 4.0% |
Source: Indian Customs (DGFT) data
JSC R-PHARM (Russia) — The Largest Single Buyer
JSC R-PHARM holds the position of the #1 importer of Bevacizumab from India, with $2.5 million in import value and 51 verified shipments. The company sources exclusively from Dr. Reddy’s Laboratories Limited, accounting for 100% of its Bevacizumab imports. Its average shipment value of $50,000 significantly exceeds the market average of $24,200.
Biocon Biologics UK Limited (Netherlands)
Biocon Biologics UK Limited ranks as the #3 importer with $855,000 in import value across 18 verified shipments. The company sources from Biocon Biologics India Limited and distributes to multiple destinations including the Netherlands, South Africa, Brazil, and Egypt.
Dr. Reddy’s Laboratories SAS (Colombia)
Dr. Reddy’s Laboratories SAS operates as a significant importer in Colombia, with $1.9 million in import value and 20 orders. The company primarily imports Persivia 100mg/4ml formulations.
Emerging Buyers and Regional Importers
Sean Dominican SRL (Dominican Republic)
Sean Dominican SRL ranks among the top importers with $1.0 million in import value across 30 shipments, representing a growing Caribbean market for Bevacizumab.
Zydus Pharmaceuticals México S.A. de C.V. (Mexico)
This Mexican entity imports Bevacizumab with a value of $1.7 million, sourcing Abemvy 400mg formulations. Mexico represents a key growth market for oncology biologics in Latin America.
State Trading Organization PLC (Maldives)
This government-linked entity serves as the primary import channel for the Maldives, with multiple import transactions totaling over $200,000.
Other Notable Buyers
Additional significant importers include:
- Well and Tech Medical Ltd. (Venezuela) — $100,000 in import value
- Dr. Reddy’s Laboratories (Thailand) — $88,100 in import value
- Movianto UK Limited (United Kingdom) — $111,300 in import value
- Dr. Reddy’s Laboratories (Pty) Ltd (South Africa) — $100,000 in import value
- Lambda Therapeutic Research Limited (India) — imports from China for research purposes
- Imperial Life Sciences Private Limited (India) — imports from China for research purposes
Sources: Various customs and trade data
Procurement Trends and Tender Activity
European Union Procurement
Government health services across Europe actively procure Bevacizumab through formal tender processes. The Health Service Executive (HSE) in Ireland has awarded contracts for Bevacizumab Concentrate for Solution for Infusion to Beaumont Hospital and Our Lady of Lourdes Hospital, Drogheda. Celltrion Healthcare Ireland Limited was selected as a winning supplier.
Spain’s INGESA has issued contracts for Bevacizumab supply, with Laboratorio STADA named as a supplier. Malta has tendered for Bevacizumab 25mg/ml preparations with an estimated value of €2,773,800.
Taiwanese Procurement
Taipei Veterans General Hospital has conducted open tenders for Bevacizumab concentrate for solution for infusion 100mg/4ml under a unit price open contract.
Albanian Procurement
Albania’s Central Purchasing Operator has included Bevacizumab in national tender processes for pharmaceutical procurement.
Bevacizumab Biosimilars: Transforming the Buyer Landscape
The bevacizumab biosimilars market is valued at USD 2.1 billion and is projected to grow at a CAGR of 8.3% to reach USD 4.3 billion by 2034. Biosimilars now account for approximately 92% of the bevacizumab market share, with Mvasi capturing the largest share at approximately 54%.
Approved Biosimilars Driving Competition
Key approved biosimilars include:
- Mvasi (Amgen) — bevacizumab-awwb
- Zirabev (Pfizer) — bevacizumab-bvzr
- Alymsys (Amneal Pharmaceuticals)
- Avzivi (Bio-Thera Solutions) — approved by the U.S. FDA in December 2023
The entry of multiple biosimilars has intensified competition and driven down costs, making Bevacizumab more accessible to healthcare systems worldwide. Europe has led biosimilar adoption, supported by well-established regulatory pathways and favorable pricing policies.
Major Biosimilar Manufacturers
Key global manufacturers of Bevacizumab biosimilars include Amgen, Amneal Pharmaceuticals, Celltrion Healthcare, Pfizer, Bio-Thera Solutions, Zhejiang Beta Pharma, Jiangsu Hengrui Pharmaceuticals, Qilu Pharma, and Shanghai Henlius Biotech. Additional manufacturers include Biocad, Biocon, Cadila Pharmaceuticals, Dr. Reddy’s, Hetero, and MAbxience.
Key Suppliers Serving Global Buyers
Understanding the supplier landscape helps buyers identify reliable sourcing partners.
Dr. Reddy’s Laboratories Ltd (India)
Dr. Reddy’s Laboratories Ltd is the #1 Indian exporter of Bevacizumab with $6.5 million in export value and 131 verified shipments across 15 countries. The company’s primary destinations include Russia (51.0%), Colombia (26.9%), and Thailand (5.9%).
Zydus Lifesciences Limited (India)
Zydus Lifesciences ranks #5 among Indian exporters with $1.1 million in export value across 21 shipments. The company supplies Bevacizumab to Mexico (52.4%), Bolivia (29.2%), and Nepal (10.2%).
Other Notable Indian Exporters
- Mylan Pharmaceuticals Private Limited — $650,000 export value, serving 5 countries
- R.S. Surgipharm Private Limited — $214,100 export value, primarily serving Kenya (99.3%)
- Biocon Biologics India Limited — primary supplier to Biocon Biologics UK
India’s Role in Global Bevacizumab Supply
India has established itself as a critical node in the global Bevacizumab supply chain. The country exported $15.2 million worth of Bevacizumab through 1,408 shipments from 196 suppliers to 100 countries. This extensive network serves 346 buyers globally, with the top buyer being JSC R-PHARM (Russia).
The India-to-China trade corridor also plays a role in the supply chain, though primarily for research-grade Bevacizumab. India’s imports from China total $768 across 4 shipments from 2 foreign suppliers, with Genscript Biotech (Singapore) Pte Ltd as the leading supplier.
Factors Influencing Global Bevacizumab Procurement
Regulatory Approvals and Market Access
Regulatory approvals significantly influence buyer behavior. The U.S. FDA’s approval of Bio-Thera Solutions’ Avzivi for lung and colorectal cancers represents a milestone in biosimilar access. Similarly, Enzene Biosciences Ltd introduced a Bevacizumab biosimilar in India for metastatic colorectal cancer treatment.
Pricing Pressures and Cost Optimization
The entry of biosimilars has created substantial pricing pressures, driving healthcare systems to reassess procurement strategies. Biosimilars offer more affordable options while maintaining comparable efficacy and safety profiles.
Healthcare Infrastructure Development
Growing healthcare infrastructure and improved diagnostic capabilities in emerging markets are enabling early detection and treatment of cancer, increasing the use of Bevacizumab. Government initiatives and funding for cancer treatment programs further support market growth.
Frequently Asked Questions
Who are the largest Bevacizumab buyers globally?
The largest Bevacizumab importers from India are JSC R-PHARM (Russia) with $18.7 million, JSC R PHARM (Russia) with $4.9 million, and Biocon Biologics UK Limited (Netherlands) with $4.9 million in import value.
How many countries import Bevacizumab?
India alone exports Bevacizumab to 100 countries, serving 346 buyers globally through 1,408 shipments.
What is the market size of Bevacizumab biosimilars?
The Bevacizumab biosimilars market is valued at USD 2.1 billion and is projected to reach USD 4.3 billion by 2034, growing at a CAGR of 8.3%.
Which companies manufacture Bevacizumab biosimilars?
Major manufacturers include Amgen (Mvasi), Pfizer (Zirabev), Amneal Pharmaceuticals (Alymsys), Bio-Thera Solutions (Avzivi), Celltrion Healthcare, and Shanghai Henlius Biotech.
How do buyers procure Bevacizumab?
Buyers procure Bevacizumab through direct import from manufacturers, government tender processes, and distribution agreements. European health services utilize formal procurement procedures, while emerging markets often rely on distributors and trading organizations.
What is the average shipment value for Bevacizumab?
The market average shipment value is approximately $24,200, though individual buyers vary. JSC R-PHARM averages $50,000 per shipment, significantly above the market average.
Is Bevacizumab on the WHO Essential Medicines List?
Yes, Bevacizumab is included on the WHO Model List of Essential Medicines for treating various cancers and ophthalmic conditions.
MERCK SHARP DOHME COMERCIALIZADORA S DE RL DE CV
ROCHE INTERNATIONAL LTD
PRODUTOS ROCHE QUIMICOS E FARMACEUTICOS S A
CÔNG TY TNHH DƯỢC PHẨM VÀ HÓA CHẤT NAM LINH
CÔNG TY TNHH XUẤT NHẬP KHẨU Y TẾ DELTA
ROCHE PRODUCTS INDIA PRIVATE LIMITED
CELLTRION HEALTHCARE DISTRIBUICAO DE PRODUTOS FARMACEUTICOS DO BRASIL LTDA
BỆNH VIỆN NHÂN DÂN GIA ĐỊNH
MERCK SHARP DOHME FARMACEUTICA LTDA
MERCK SHARP DOHME PERU S R L
PFIZER BRASIL LTDA
CÔNG TY TNHH ROCHE PHARMA VIỆT NAM
URUFARMA S A
ROCHE CHILE LIMITADA
ROCHE PAKISTAN LIMITED
LABORATORIOS PFIZER LTDA
MURRY S A
ROCHE FARMA PERU S A
LABORATORIOS SOPHIA SA DE CV
PRODUCTOS ROCHE SA DE CV
WARNER LAMBERT DEL URUGUAY S A
GLOBAL MEDICAL LOGISTICS S A
LIBBS FARMACEUTICA LTDA
AMGEN MEXICO SA DE CV
PHARMEVO PRIVATE LIMITED
BIONOVIS S A COMPANHIA BRASILEIRA DE BIOTECNOLOGIA FARMACEUTICA
CHI NHÁNH CTY TNHH ZUELLIG PHARMA VIỆT NAM
AMGEN BIOTECNOLOGICA S A S
HETERO HEALTHCARE LIMITED
LABORATORIOS RICHMOND SACIF
AMBITECH BIOPHARMACEUTICALS INC
ZUELLIG PHARMA CORPORATION
JOHNSON JOHNSON PRIVATE LIMITED
ZUELLIG PHARMA CORP
IMPERIAL LIFE SCIENCES PRIVATE LIMITED
KORLE BU TEACHING HOSPITAL
PRODUCTOS ROCHE S A QUIMICA E INDUSTRIAL
QUINTILES COLOMBIA LTDA
CELLTRION HEALTHCARE PERU S A C
INTAS PHARMACEUTICALS LIMITED
MONTE VERDE S A
ACCORD HEALTHCARE KENYA LIMITED
BRISTOL MYERS SQUIBB FARMACEUTICA LTDA
LABORATORIOS LIOMONT SA DE CV
MERCK SHARP DOHME I A LLC
PT AMAROX PHARMA GLOBAL
AMGEN BIOTECNOLOGIA DE ARGENTI
BEACON PHARMACEUTICALS PLC
HEALTHCARE PHARMACEUTICALS LTD
INTELIGENCIA EN SOLUCIONES REGULATORIAS SA DE CV
ROCHE KENYA LIMITED
AMGEN BIOTECNOLOGIA DO BRASIL LTDA
CCL PHARMACEUTICALS PVT LIMITED
LABORATORIO DE PRODUCTOS ETICOS COMERCIAL E INDUSTRIAL SA
LABORATORIOS LEGRAND SA
MEDSCRIBE LIMITED
PHARMADN SA
TEXAS CANCER CENTRE LIMITED
ТОО СК ФАРМАЦИЯ
BIO RAD LABORATORIES INDIA PRIVATE LIMITED
GYNOPHARM SOCIEDAD ANONIMA
QUINTILES MEXICO S DE RL DE CV
ZYDUS PHARMACEUTICALS MEXICO SA DE CV
FARMINDUSTRIA S A
PFIZER SOCIEDAD DE RESPONSABILIDAD LIMITADA
PT KALBIO GLOBAL MEDIKA
QUALIMED PHARMA INC
SANDOZ DO BRASIL INDUSTRIA FARMACEUTICA LTDA
SEVEN PHARMA COLOMBIA S A S
SWEDEN GHANA MEDICAL CENTRE LIMITED
AMAROX PHARMA SA DE CV
FARMEDICAL S R L
FRESENIUS KABI INDIA PRIVATE LIMITED
MEDSERV AFRICA LIMITED
PFIZER SA DE CV
PRODS ROCHE S A
RIOMAR COMERCIAL IMPORTADORA E EXPORTADORA LTDA
ADIUM PHARMA S A
CELLTRION HEALTHCARE DE MEXICO SA DE CV
CÔNG TY TNHH PFIZER VIỆT NAM
DR REDDY S LABORATORIES LTD
ERONGOMED HEALTH DISTRIBUTORS PTY LTD
ESKAYEF PHARMACEUTICALS LIMITED
GLOBO ASIATICO ENTERPRISES INC
ICLOS URUGUAY S A
INCEPTA PHARMACEUTICALS LIMITED
MERCK SHARP AND DOHME COLOMBIA S A S
PHARMARIS PERU S A C
UGANDA CANCER INSTITUTE
LABORATORIOS RECALCINE S A
LUPIN LIMITED
ROCHE PRODUCTS GHANA LIMITED
SCORP MEDITECH LIMITED
SIGMA ALDRICH CHEMICALS PRIVATE LIMITED
STRENUUS MARKETING S A S
ГУ ЦЕНТР БЕЗОПАСНОСТИ ФАРМАЦЕВТИЧЕСКОЙ ПРОДУКЦИИ
ABBVIE FARMACEUTICA LTDA
ARISTOPHARMA LTD CHANGE FROM
BOEHRINGER INGELHEIM SA
CÔNG TY CỔ PHẦN DƯỢC PHẨM OPV
CÔNG TY CỔ PHẦN DƯỢC PHẨM TRUNG ƯƠNG CPC1
GALAXY PHARMACEUTICAL LIMITED
INSTITUTO SANITAS S A
KALBE FARMA
KRISHGEN BIOSYSTEMS
LABS SERVIER DE COLOMBIA S A S
MEDMART PHARMA PVT LTD
NOVARTIS BIOCIENCIAS SA
PHARMAMED SOLUTION LIMITED
PT ETANA BIOTECHNOLOGIES INDONESIA
ROCHE MUSTAHZARLARI SANAYI ANONIM SIRKETI
TECNOFARMA S A
THERMO FISHER SCIENTIFIC BRASIL SERVICOS DE LOGISTICA LTDA
CEFA CENTRAL FARMACEUTICA SOCIEDAD ANONIMA
DIVASA PHARMA LTD
EVEREST PHARMACEUTICALS LIMITED
EXELTIS S A S
INSPIRE PHARMACEUTICALS LIMITED
M S HELIX PHARMA PVT LTD
METISKA FARMA
NOVARTIS DE COL S A
ONCOPHARM U LTD
PHARMA CHOICE
PT METISKA FARMA
QUINTILES CHILE
RADIANT PHARMACEUTICALS LTD CHANGE
RIOMAR TRADING LTDA
RIPPLE PHARMACEUTICALS LIMITED
RPG LIFE SCIENCES LIMITED
SURYA PHARMA LIMITED
UNITED STATES PHARMACOPEIA INDIA PRIVATE LIMITED
ADAMEY CAM ED BUSAIN
AUROVIDA FARMACEUTICA SA DE CV
BB ASSOCIATES LIMITED
BIOMM S A
BOLIVAR PARIENTE CASTILLERO
CADILA PHARMACEUTICALS LIMITED
CÔNG TY TNHH ASTRAZENECA VIỆT NAM
DROGUERIA SARO S A
ELEA PERU S A C
INNOVAPHARMA S R L
JANSSEN CILAG SA DE CV
JEEVAN SCIENTIFIC TECHNOLOGY LIMITED
KALBE FARMA TBK
KALBIO GLOBAL MEDIKA
KRISHGEN BIOSYSTEMS PRIVATE LIMITED
KRISHNA CHEMISTS LIMITED
LABORATORIO LIBRA SOCIEDAD ANONIMA
LABORATORIO TEUTO BRASILEIRO S A
LAMBDA THERAPEUTIC RESEARCH LIMITED
LEISA ONCO CENTER SOCIEDAD ANONIMA
LLC STADA SUBSIDIARY
MEDETHIX INC
MEDICINE SA
MERCK SHARP AND DOHME IA LLC
MIRYAM AIDA LUZ ARGANDONA MOLINA
MIRYAM AIDA LUZ ARGANDOÑA MOLINA
NULIFE CONSULTANTS AND DISTRIBUTORS PRIVATE LIMITED
PILL PACK HEATHCARE LIMITED
POPULAR PHARMACEUTICALS PLC
PT KALBE FARMA TBK
QUIMFA S A
REDDYS PHARMA LIMITED
ROYAL MEDICAL PRIVATE LIMITED
SCORPIO SOLUTIONS LIMITED
SEVEN PHARMA NICARAGUA SOCIEDAD A
THE EAH CARE LIMITED
THE SEARLE COMPANY LIMITED
UGANDA CANCER INSTITUTE KAMPALA KAWEMPE DIVISION SOUTH KAWEMPE DIVISION MULAGO COMPLEX MULAGO UPPER
VMG PHARMA S A
WORLD MEDICINE ILAC SAN VE TIC A S
ZISKA PHARMACEUTICALSLIMITED
ИП ООО STADA SUBSIDIARY
ТОВ ДР РЕДДІ С ЛАБОРАТОРІЗ 08320 КИЇВСЬКА ОБЛ БОРИСПІЛЬСЬКИЙ Р Н С В ОЛЕКСАНДРІВКА ВУЛ КИ
ACEC SOLUCIONES MEDICAS CA
ADVANCED CHEMICAL INDUSTRIES LTD
ALLIANZ BIOINNOVATION
ARAMEX LANKA PVT LTD
ASTRAZENECA COLOMBIA SAS
ASTRAZENECA SA DE CV
AVILA CHEMIST LIMITED
BEXIMCO PHARMACEUTICALS LIMITED
BIOCON BIOLOGICS LIMITED
BIOCON BIOLOGICS LIMITED BSEZ UNIT
BIOMEDICAL LIFE SCIENCES
C O JOCYL TAGACTAC
CELLTRION HEALTHCARE CHILE SPA
CELLTRION HEALTHCARE COLOMBIA SAS
COSPHARM INVESTMENTS PTY LTD
CURATEQ BIOLOGICS PRIVATE LIMITED
CÔNG TY CỔ PHẦN KỸ THUẬT VÀ SINH HỌC ỨNG DỤNG VIỆT NAM
DENOVO TECHNOLOGIES
DHL INTERNATIONAL NIGERIA LIMITED
DRUG INTERNATIONAL LIMITED
ETANA BIOTECHNOLOGIES INDONESIA
EUROFARMA LABORATORIOS S A
EVERON LIFE SCIENCES
EXAPILOG PRIVATE LIMITED
FISHER BIOPHARMA SERVICES INDIA PVT LTD
G2 PHARMACY
GLOBE BIOTECH LIMITED
GOLD TREE PHARMACEUTICALS LTD
HEALTH POWER PHARMACEUTICALS LIMITED
HELIX PHARMA PVT LTD
IQVIA RDS BRASIL LTDA
IQVIA RDS INDIA PRIVATE LIMITED
IQVIA TIBBI ISTATISTIK TICARET VE MUSAVIRLIK LIMITED SIRKETI
JOHNSON AND JOHNSON PRIVATE LIMITED
KENT PHARMACEUTICALS KENYA LIMITED
LAB FRANCO COLOMBIANO LAFRANCOL S A S
LABORATORIOS FARMACEUTICOS LAFAR SA
LUCKY DEVELOPMENT CORP PHARMACY 4
MACTER INTERNATIONAL LIMITED
MACTER INTERNATIONAL LTD
MARKSS H L C PVT LTD
MERU DOCTORS PLAZA LIMITED
MYLAN BRASIL DISTRIBUIDORA DE MEDICAMENTOS LTDA
NANOLEK LLC
NATIONAL INSTITUTE OF BIOLOGICALS
NULIFE CONSULTANTS AND DISTRIBUTORS PRIVATE LIMITE
ORGANON FARMACEUTICA LTDA
PFIZER SAS
PROMOTION MEDICALE ET DIS
PSM PHARMACEUTICALS LIMITED
PT CKD OTTO PHARMACEUTICALS
REYMARK BIROG
SAI LIFE SCIENCES LIMITED
SEVEN PHARMA PANAMA
SYNEOS HEALTH BRASIL LTDA
THE ACME LABORATORIES LIMITED
VALERIAN CHEM PRIVATE LIMITED
VARIFARMA PERU S A C
ZYDUS LIFESCIENCES LIMITED
ТОВ ДР РЕДДІ С ЛАБОРАТОРІЗ 08320 КИЇВСЬКА OБЛ БOРИСПІЛЬСЬКИЙ Р Н С В ОЛЕКСАНДРІВКА ВУЛ КИЇ
Conclusion
The global Bevacizumab buyer landscape reflects the broader transformation occurring in oncology biologics procurement. With biosimilars now accounting for over 92% of market share and the overall market projected to reach USD 18.46 billion by 2034, pharmaceutical sourcing professionals must navigate an increasingly complex network of suppliers, regulatory pathways, and procurement mechanisms.
Key takeaways for procurement specialists include the concentration of buyer power among a few large importers, the critical role of Indian manufacturers in global supply, and the accelerating shift toward biosimilar adoption across both established and emerging markets. Understanding these dynamics enables informed decision-making and strategic sourcing in the rapidly evolving Bevacizumab market.
